.jpg?w=340&itok=xrpB93pQ "IPT discussed in technical publications."){kind=icon}
Recent regulatory shifts have critical implications for how biosimilar developers generate and prioritise information. Read ICON’s latest article in PharmTech Magazine, to learn what these changes mean for data collect...
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Communicating for change - creating effective medical communications
Chris O'Toole, VP Commercial Solutions, discusses best practices for medical communications to improve interactions and results.
-
Recent advances and future challenges using biomarkers in oncology precision medicine
Dr. Brian Huber outlines the role biomarkers play in guiding therapeutic strategies.
-
Clinical Research: One of Ireland's most promising industries
ICON CEO Dr. Steve Cutler discusses clinical research as one of Ireland’s most promising industries in this special supplement on Ireland’s economy that appeared in the weekend edition of the New York Times.
-
Overcoming data flow challenges in cell therapy trials
How data flows in cell therapy studies differ from other studies and strategies to manage the high volume of data in CGT trials is highlighted in this Q&A with ICON expert Olivier Saulin.
-
Innovation in clinical trial methodologies
In this podcast, Dr. Peter Schueler, Senior VP Drug Development Services, Neurosciences at ICON, talks about topics discussed in a timely new book he edited titled Innovation in Clinical Trial Methodologies.
-
Pharma’s coming home
Seth Nelson, Senior Director of Patient Recruitment and Clinical Research Services, provides expert commentary on patient centricity during the pandemic.
-
Ensuring better patient outcomes through decentralised & hybrid trials
ICON CEO Steve Cutler discusses how the research industry has changed in the past year, concluding that decentralised models are helping to improve patient outcomes and bring treatments to market faster (page 12).
-
.jpg?w=545&itok=Rwqj2ePn "IPT discussed in technical publications.")
Anatomic pathology in the digital era
Greg Cox, Director ICON Laboratory Services, shares his perspective on how integrating digital pathology into clinical trials can benefit study outcomes and data integrity.
-
Trailblazing women stress importance of diversity in pharma
Nuala Murphy, President of Clinical Research Services at ICON, discusses how increasing diversity is a key area of focus for ICON, both in terms of patient diversity and diversity in the organisation.
-
The central role of Interactive Response Technology in today's clinical trials
Michelle Lynskey, Global Head of Interactive Response Technology and Clinical Supplies Management, offers her insights on the role of IRT in clinical trials (pages 42-43).
